General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-08-15 | 2022-06 | -0.55 | N/A | N/A | N/A |
2022-05-13 | 2022-03 | -0.63 | N/A | N/A | N/A |
2022-03-31 | 2021-12 | 0 | N/A | N/A | N/A |
2021-11-15 | 2021-09 | -0.68 | N/A | N/A | N/A |
2011-09-01 | 2011-06 | 0 | N/A | N/A | N/A |
2011-06-04 | 2011-03 | 0 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-09-16 | Morgan Stanley | Upgrade | Underweight | |
2022-05-17 | Morgan Stanley | Upgrade | Underweight | |
2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
2021-12-22 | Jefferies | Downgrade | Buy | Hold |
2021-12-15 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
2021-12-15 | Guggenheim | Downgrade | Buy | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2021-08-09 | ADIMAB, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 27.85M | Conversion of Exercise of derivative security |
2022-08-18 | ELIA MARC | Director | 0.00 | Purchase |
2021-08-09 | GERNGROSS TILLMAN U. | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2022-08-31 | HERING DAVID | Chief Executive Officer | 8.00K | Purchase |
2021-08-09 | MCGUIRE TERRANCE G | Director | 0.00 | Purchase |
2021-08-09 | MITHRIL II, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | FMR, LLC | 15.23M | 70.68M | 14.00% |
2022-06-29 | M28 Capital Management LP | 6.40M | 29.69M | 5.88% |
2022-06-29 | Orbimed Advisors LLC. | 5.06M | 23.46M | 4.65% |
2022-06-29 | Slate Path Capital, LP | 3.74M | 17.33M | 3.43% |
2022-06-29 | 683 Capital Management LLC | 3.60M | 16.72M | 3.31% |
2022-06-29 | Vanguard Group, Inc. (The) | 3.30M | 15.32M | 3.03% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-07-30 | Fidelity Growth Company Fund | 5.06M | 23.50M | 4.65% |
2022-06-29 | Vanguard Total Stock Market Index Fund | 1.62M | 7.52M | 1.49% |
2022-06-29 | Fidelity Growth Company K6 Fund | 1.33M | 6.18M | 1.22% |
2022-07-30 | iShares Russell 2000 ETF | 1.24M | 5.74M | 1.14% |
2022-06-29 | Fidelity Series Growth Company Fund | 1.23M | 5.71M | 1.13% |
2022-06-29 | Vanguard Small-Cap Index Fund | 691.96K | 3.21M | 0.64% |
Bought at 4.70. 140 shares only.
Mr. Hering is a seasoned life sciences leader with more than 25 years of industry experience, having spent much of his career leading functions within vaccine franchises at some of the top pharmaceutical companies. Prior to joining Adagio, Mr. Hering led Pfizer’s mRNA Global Franchise and launched its COVID-19 vaccine as president, North America. Mr. Hering holds an M.B.A. from Harvard Business School and a B.S. in operations research and industrial engineering from Cornell University.
$ADGI now lets not give away any cheap shares to stop loss raids
$OCGN $player $switch $to $ADGI
$FDAapproves
$BUY!!!! $FDApreapproved
$ADGI Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET.
A live webcast will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.
About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, if authorized or approved by regulatory authorities, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.